HDAC9 and breast carcinoma: Studies have shown that histone deacetylase (HDAC) inhibitors can stimulate LIFR, even reversing the suppression of LIFR by hypoxia and PTHrP, thereby inducing a dormant phenotype in breast cancer cells43.